

**THE EFFECTIVITY OF ANNONA MURICATA TO REDUCE  
IL-12 LEVEL AND NUMBER OF LEUKOCYTE AND  
IMPROVE MONOCYTE PERCENTAGE  
(STUDY IN CEREBRAL MALARIA OF SWISS ALBINO MICE)**



**Thesis  
For requirements master degrees**

**Master of Biomedical Sciences**

**WALID. FARAJ. A. NAAMAT  
NIM : 22010113429016**

**FACULTY OF MEDICINE  
DIPONEGORO UNIVERSITY  
SEMARANG  
2015**

**APPROVAL PAGE**

**THE EFFECTIVITY OF ANNONA MURICATA TO REDUCE IL-12  
LEVEL AND THE NUMBER OF LEUKOCYTE  
AND INCREASE MONOCYTE  
(STUDY IN CEREBRAL MALARIA OF SWISS ALBINO MICE)**

By:  
WALID FARAJ A. NAAMAT  
NIM : 22010113429016

Will be defend in front of the defence committee  
on August 25<sup>th</sup>, 2015  
and has been approved by,

Supervisor I,

Supervisor II,

Dr. dr. RA. Kisdjamiatun RMD, M.Sc.  
NIP. 196401301990032001

Prof. Dr. dr. Tri Nur Kristina, DMM., M.Kes.  
NIP. 19590527 198603 2 001

Approved by,

Head of Master Degree Program in Biomedical Sciences  
Faculty of Medicine Diponegoro University

dr. A. Zulfa Juniarto, M.Si.Med., Sp.And., Phd.  
NIP. 197006081997021001

## **DECLARATION**

I hereby declare that this thesis is my own work and has not been submitted in any form for another degree or diploma at any university or other institution of tertiary education, there are no elements belonging to plagiarism as defined in Decree No 17 of 2010. Information derived from the published or unpublished work of others has been acknowledged in the text and a list of references is given.

Semarang, August, 2015

WALID FARAJ A. NAAMAT

## CURRICULUM VITAE

### A. Identity

Name : WALID FARAJ A. NAAMAT

Sex : Male

Place and Date of Birth : S. Khamis, Libya /September 14<sup>th</sup>, 1987

Religion : Muslim

Address : Alkhoms , Libya

### B. Educational Background

No	Name of School/Institution	Location	Degree	Year
1	Abi Azza	Abi Azza /Alkhoms , Libya	Primary	2001
2	Alestiklal	Alestiklal /Alkhoms , Libya	Secondary	2005
3	Azzaytuna University	Bani Walid , Libya	Bachelor	2011
4	Diponegoro University	Semarang, Central Java, Indonesia	Master Program	2015

### C. Job Experience

1. 2012 – 2014 : Laboratory technician in Emhemed Ben Ibrahim Clinic

### D. Family History

1. Name of father : Faraj Abdualsalam Naamat
2. Name of mother : Fatma Husien Almadhon

## FOREWORD

Assalamu'alaikum Wr. Wb.

Praise to Allah Almighty for all grace and guidance that thesis with the title **“The Effectivity of *Annona Muricata* to Reduce IL-12 Level and Number of Leukocyte and Improve Monocyte Percentage (Study in Cerebral Malaria of Swiss Albino Mice)”** can be resolved. This thesis is structured to meet one of the requirements to obtain a Master degree in Biomedical Sciences (MSi. Med) in the field of Immunology at the Faculty of Medicine, University of Diponegoro.

I realized that without the help and guidance of the various parties, it is not easy for me to finish this thesis. Therefore, on this occasion, the author would like to express respect and gratitude as possible to:

1. Rector of Diponegoro University who has provided an opportunity for authors to improve science learning.
2. Dean of the Faculty of Medicine, University of Diponegoro who has provided the opportunity for the author to participate in education.
3. Chairman Master of Biomedical Sciences Faculty of Medicine, University of Diponegoro who has provided motivation and support to the author to complete his education on time.
4. Dr. dr. RA. Kisdjamiatun RMD, M.Sc. as the First Counselor who has been willing to invest time, energy and mind to guide the writer for completing this thesis.

5. Prof. Dr. dr. Tri Nur Kristina, DMM., M.Kes. as the Second Counselor who has been willing to take the time, effort, and thought to guide the writer for completing this thesis.
6. dr. Sudaryanto, M.Pd.Ked, as the Head of the Laboratory of Parasitology, Faculty of Medicine, University of Diponegoro and the entire laboratory staff who have given permission Parasitology and support for research.
7. Prof. Sultana M. Faradz, PhD. and the entire staff Laboratory Cebior who have given permission and support for research.
8. Dr. MI. Tjahjati DM, SpPK. as Head of Laboratory GAKI and the entire staff Laboratory GAKI who have given permission and support for research.
9. dr. Noorwijayahadi, M.Kes. and the entire staff of the Laboratory of Pharmacology of the Faculty of Medicine, University of Diponegoro who have helped me during the study.
10. Professors and Lecturers in the Master of Biomedical Sciences Faculty of Medicine, University of Diponegoro who has given his knowledge during his education writer.
11. All employees / academic staff in the program as Master of Biomedical Sciences Faculty of Medicine, University of Diponegoro who have provided assistance for the author was educated.
12. Parents and the whole loved ones who have given prayers and support during the authors studied.

13. Fellow students of Master of Biomedical Sciences Faculty of Medicine, University of Diponegoro 2014 which has been jointly studying and providing support to authors.

14. To all those who have a lot to provide assistance, but can not mention one by one author.

With limited knowledge, the authors expect criticism and constructive suggestions for the perfection of this thesis.

Finally, the authors hope that Allah is pleased to reply to all the good of all those who have helped this thesis. Hopefully, this thesis can be useful for the development of science, especially Biomedicine.

Wassalamualaikum Wr. Wb.

Semarang, August, 2015

Writer

## TABLE OF CONTENTS

	Page
Cover .....	i
Approval .....	ii
Declaration .....	iii
Curriculum Vitae .....	iv
Foreword .....	v
Table of Contents .....	viii
List of Abbreviations .....	xi
List of Figures .....	xiii
List of Table .....	xiv
List of Graphs .....	xv
List of Appendixes .....	xvi
Abstract .....	xvii
Abstrak .....	xviii
CHAPTER I INTRODUCTION .....	1
1.1. Background .....	1
1.2. Research Questions .....	4
1.3. Research Objective .....	4
1.3.1. General Objective .....	4
1.3.2. Specific Objective .....	4
1.4. Research Benefits .....	4
1.5. Research Originality .....	5
CHAPTER II LITERATURE REVIEW .....	7
2.1. Malaria .....	7
2.1.1 Life Cycle <i>Plasmodium falciparum</i> .....	7
2.1.2 Pathogenesis of Malaria .....	8
2.1.3 Parasitemia .....	11

2.1.4	Leukocyte in Malaria .....	12
2.1.4.1	Leucocytosis in Malaria .....	13
2.1.4.2	Relation of Leukocytes in Malaria.....	15
2.2	Interleukin12 (IL-12) .....	15
2.2.1	Structure of IL-12 .....	16
2.2.2	Function of IL-12.....	16
2.2.3	Role and Regulation of IL-12 in Malaria.....	17
2.2.4.	Factors that Influence the Production of IL-12.....	19
2.3	<i>Plasmodium berghei</i> ANKA .....	20
2.3.1	Taxonomy <i>Plasmodium berghei</i> ANKA.....	20
2.4	<i>Annona muricata</i> Linn. ....	21
2.4.1	Pharmacology of <i>Jatropha multifida</i> Linn. ....	23
2.5	Spleen in Malaria .....	25
2.6	Spleen in PbA Infected Mice .....	26
2.7	Theoretical Framework .....	29
2.8	Conceptual Framework .....	32
2.9	Hypothesis .....	32
2.9.1	Major Hypothesis .....	32
2.9.2	Minor Hypothesis.....	32
CHAPTER III	RESEARCH METHOD .....	33
3.1	Scope of Study .....	33
3.2	Design of Study .....	33
3.3	Population and Sample .....	35
3.3.1	Population .....	35
3.3.2	Sample .....	35
3.3.3	Sample Size .....	35
3.3.4	Inclusion Criteria .....	36
3.3.5	Drop Out .....	36
3.4	Variable of Study .....	36
3.5	Operational Definition .....	37
3.6	Data Analysis .....	37

3.7	Research Instrument and Consumables .....	37
3.7.1	Instrument .....	37
3.7.2	Consumable Materials .....	38
3.8	Study Protocol .....	38
3.9	Research Flow .....	40
3.10	Data Collection .....	41
CHAPTER IV	RESULT AND DISCUSSION .....	42
4.1.	Result .....	42
4.1.1.	Description Data of IL-12 .....	42
4.1.2.	Statistic Analysis of IL-12 .....	43
4.1.3.	Description Data of Total Leukocyte .....	45
4.1.4.	Statistical Analysis Number of Leukocyte .....	45
4.1.5.	Description Data of Monocyte Percentage .....	47
4.1.6.	Statistical Analysis of Monocyte Percentage .....	48
4.2.	Discussion .....	49
4.2.1.	IL-12 .....	49
4.2.2.	Number of Leukocyte and Monocyte Percentage .....	53
4.3.	Limitation of the Study .....	59
CHAPTER V	CONCLUSION AND SUGGESTION .....	60
5.1.	Conclusion .....	60
5.2.	Suggestion .....	60
References	.....	61
Appendix	.....	79

## LIST OF ABBREVIATIONS

APCs	: <i>antigen presenting cells</i>
CD4	: <i>cluster differentiation 4</i>
CD8	: <i>cluster differentiation 8</i>
CD30	: <i>cluster differentiation 30</i>
CM	: <i>Cerebral Malaria</i>
CTL	: <i>Cytotoxic T lymphocytes</i>
DCs	: <i>Dendritic cells</i>
EBV	: <i>Epstein-Barr virus</i>
ECM	: <i>Experiment cerebral malaria</i>
IFN- $\gamma$	: <i>Interferon-gamma</i>
IL-2	: <i>Interleukin 2</i>
IL-4	: <i>Interleukin 4</i>
IL-10	: <i>Interleukin 10</i>
IL-12	: <i>Interleukin 12</i>
MLR	: <i>Monocyte-Lymphocyte Ratio</i>
NK	: <i>Natural killer</i>
NLR	: <i>Neutrophil-lymphocyte Ratio</i>
PbA	: <i>Plasmodium berghei ANKA</i>
PF4	: <i>Platelet Factor 4</i>
PBMC	: <i>Peripheral blood monocular cells</i>
PHA	: <i>phytohemagglutinin</i>
Th 1	: <i>Type 1T helper cells</i>

TNF- $\alpha$  : *Tumor necrosis factor alpha*

WBCs : *White blood cells*

## LIST OF FIGURES

Figure 2.1. Pathogenesis of Malaria .....	11
Figure 2.2. <i>Annona muricata</i> Linn.....	21
Figure 2.3. Theoretical Framework .....	31
Figure 2.4. Conceptual Framework .....	32
Figure 3.1. Design of Study .....	33
Figure 3.2. Research Flow .....	40

## LIST OF TABLES

Table 1.1.	Previous report related to study .....	5
Table 3.1.	Operational Definition .....	37
Table 4.1.	Post Hoc Analyses of IL-12 Concentration of Research Groups With or Without <i>P. berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	44
Table 4.2.	Post Hoc Analysis of The Leukocyte Number of Research Group With or Without <i>P. berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	47
Table 4.3.	Post Hoc Analysis of Monocyte Percentages of Research Group With or Without <i>P. berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	49

## LIST OF GRAPH

Graph 4.1.	Mean of IL-12 Research Group With or Without <i>P.berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	42
Graph 4.2.	Mean Number of Leukocyte Research Group With or Without <i>P.berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	45
Graph 4.3.	Monocytes percentage Research Group With or Without <i>P.berghei</i> ANKA Inoculation and <i>Annona muricata</i> Treatment .....	47

## LIST OF APPENDIX

Appendix 1.	Preparation Extracts of <i>Annona muricata</i> Leaves .....	79
Appendix 2.	Index Calculation Parasitemia Mice Donor .....	80
Appendix 3.	Making the Inoculums From Donor Mice .....	82
Appendix 4.	Calculation of Cells in Cell Culture Spleen .....	83
Appendix 5.	Weight Data of Swiss Mice .....	84
Appendix 6.	Descriptive Test Results Leukocytes and Monocytes .....	86
Appendix 7.	Descriptive Test Results IL-12 .....	87
Appendix 8.	Normality Test Leukocyte .....	88
Appendix 9.	Normality Test Monocytes .....	89
Appendix 10.	Normality Test IL-12 .....	90
Appendix 11.	One Way Anova Test of Leukocyte .....	91
Appendix 12.	Anova Test of Monocyte .....	94
Appendix 13.	One Way Anova Test of IL-12 .....	97
Appendix 14.	Ethical Clearance .....	100
Appendix 15.	Certificate of Analysis <i>Annonae muricatae Folium</i> .....	101
Appendix 16.	Documentation of Research .....	102

## ABSTRACT

### THE EFFECTIVITY OF ANNONA MURICATA TO REDUCE IL-12 LEVEL AND NUMBER OF LEUKOCYTE AND IMPROVE MONOCYTE PERCENTAGE (STUDY IN CEREBRAL MALARIA OF SWISS ALBINO MICE)

Walid Faraj A. Naamat, RA. Kisdjamiatun, Tri Nur Kristina

**BACKGROUND:** Many researches were documented through the investigation on ethnopharmacological use of *Annonaceae* plants to treat malaria including *Annona muricata*. This research to prove that *Annona muricata* treatment reduce IL-12 production and the number of leukocytes and percentage of monocyte during CM phase in Swiss albino mice inoculated with *Plasmodium berghei* ANKA.

**METHOD:** Study design was experimental study. 36 swiss mice which divided into 6 groups. K(-) is healthy mice, P1 and P2 were group without inoculated PbA with *A. muricata* dosage 100 and 150 mg/kg BW. K(+) is group with inoculated PbA, P3 and P4 were group with inoculated PbA and *A. muricata* dosage 100 and 150 mg/kg BW. Blood was taken from the eyes of mice for leukocyte and monocyte. IL-12 taken from the spleen detected using the ELISA method.

**RESULT:** Mean of IL-12: K(-): 0.7646; P1: 4.9834; P2: 3.0402; K(+): 3.5989; P3: 3.3647; and P4: 4.9558. Mean number of leukocyte: K(-): 12,550; P1: 9,620; P2: 13,660; K(+): 21,600; P3: 20,483; and P4: 26,433. Mean of monocyte percentage: K(-): 6.33; P1: 5.40; P2: 8.20; K(+): 4.80; P3: 3.50; and P4: 5.50.

**CONCLUSION:** The extract of *A. muricata* and PbA inoculation significantly affect the levels of IL-12. The extract of *A. muricata* and PbA inoculation significantly affect the number of leukocytes. The extract of *A. muricata* and PbA inoculation significantly affect the percentage of monocytes.

**Keywords:** *Annona muricata*, *P. berghei* ANKA, IL-12, Leukocyte, Monocyte.

## ABSTRAK

### **PENGARUH SIRSAK UNTUK MENURUNKAN LEVEL IL-12 DAN JUMLAH LEUKOSIT DAN MENINGKATKAN PERSENTASE MONOSIT (STUDI PENYAKITMALARIA SEREBRAL PADA SWISS ALBINO MICE)**

**Walid Faraj A. Naamat, RA. Kisdjamiatun, Tri Nur Kristina**

**LATAR BELAKANG:** Banyak penelitian yang didokumentasikan mengenai penggunaan ethnopharmacological tanaman *Annonaceae* untuk mengobati malaria termasuk *Annona muricata*. Penelitian ini membuktikan bahwa *Annona muricata* mengurangi produksi IL-12 dan jumlah leukosit dan persentase monosit selama fase CM pada tikus albino Swiss diinokulasi dengan *Plasmodium berghei* ANKA.

**METODE:** Desain penelitian adalah studi eksperimental. 36 tikus swiss yang terbagi menjadi 6 kelompok. K (-) adalah tikus yang sehat, P1 dan P2 adalah kelompok tanpa diinokulasi PbA dengan dosis *A. muricata* 100 dan 150 mg / kg BB. K (+) adalah grup dengan diinokulasi PbA, P3 dan P4 adalah kelompok dengan diinokulasi PbA dan dosis *A. muricata* 100 dan 150 mg / kg BB. Darah diambil dari mata tikus untuk leukosit dan monosit. IL-12 yang diambil dari limpa dideteksi dengan menggunakan metode ELISA.

**HASIL:** Rata-rata IL-12: K(-): 0.7646; P1: 4.9834; P2: 3.0402; K(+): 3.5989; P3: 3.3647; and P4: 4.9558. Rata-rata leukosit: K(-): 12,550; P1: 9,620; P2: 13,660; K(+): 21,600; P3: 20,483; and P4: 26,433. Rata-rata persentase monosit: K(-): 6.33; P1: 5.40; P2: 8.20; K(+): 4.80; P3: 3.50; and P4: 5.50.

**KESIMPULAN:** Ekstrak *A. muricata* dan PbA inokulasi secara signifikan mempengaruhi tingkat IL-12. Ekstrak *A. muricata* dan PbA inokulasi secara signifikan mempengaruhi jumlah leukosit. Ekstrak *A. muricata* dan PbA inokulasi secara signifikan mempengaruhi persentase monosit.

**Kata kunci:** *Annona muricata*, *P. berghei* ANKA, IL-12, Leukosit, Monosit.